- Oral and Poster Presentations to Highlight Preclinical Research for ARCUS® Gene Editing

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that three abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for one oral and two poster presentations at the upcoming Congress on October 11-14, 2022, at the Edinburgh International Conference Centre.

Oral Presentation:

Title: Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate Hepatitis B virus in vivo Date and Time: Wednesday, October 12, 2022, 8:30 AM - 10:40 AM BST Session Title: Parallel 2a, Vaccine technologies & infectious diseases Location & Poster Number: Pentland and Sidlaw, OR14 Presenter: Derek Jantz, Ph.D., Chief Scientific Officer & Strategy

Poster Presentations:

Title: ARCUS gene editing of Apolipoprotein C3 results in substantial reduction in serum triglycerides in vivo Date and Time: Wednesday, October 12, 2022, 7:30 PM - 9:00 PM BST Session Title: Gene and epigenetic editing Location & Poster Number: Cromdale Hall, Level 2, Poster# P441 Presenter: Wendy Shoop, Scientist

Title: Specific elimination of m.3243A>G mutant mitochondrial DNA using mitoARCUS in cultured cells and a novel xenograft mouse model Date and Time: Thursday, October 13, 2022, 5:30 PM - 7:15 PM BST Session Title: Gene and epigenetic editing Location & Poster Number: Cromdale Hall, Level 2, Poster #P422 Presenter: Wendy Shoop, Scientist

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple ex vivo “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

Investor Contact: Mei Burris Director, Investor Relations and Finance Mei.Burris@precisionbiosciences.com

Media Contact: Maurissa Messier Senior Director, Corporate Communications Maurissa.Messier@precisionbiosciences.com

Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Precision BioSciences Charts.
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Precision BioSciences Charts.